iNDICA NEWS BUREAU-
A third Covid wave in India is ‘inevitable’, and it could hit the country in the next six to eight weeks, AIIMS chief Dr. Randeep Guleria told news channels on Saturday, June 19.
The country’s main challenge is vaccinating a huge population and the increase in dose gaps for Covishield “may not be a bad” approach to provide protection to cover more people, he explained.
A new frontier will have to be developed in India’s fight against Covid to further study the mutation of the virus, Dr. Guleria stressed, as he talked about the new Delta-plus variant, which has evolved from the Delta variant of COVID-19, triggering fresh concerns about monoclonal antibody treatment.
“As we have started unlocking, there is again a lack of Covid-appropriate behavior. We don’t seem to have learned from what happened between the first and the second wave. Again crowds are building up… people are gathering. It will take some time for the number of cases to start rising at the national level. Third-wave is inevitable and it could hit the country within the next six to eight weeks… maybe a little longer,” Dr. Guleria said.
Nearly 5 percent of the country’s population has so far been vaccinated with two doses. The government aims to vaccinate 108 crore of over 130 crore people in the country by the end of this year.
“That (vaccination) is the main challenge. A new wave can usually take up to three months but it can also take much lesser time, depending on various factors. Apart from Covid-appropriate behavior, we need to ensure strict surveillance. Last time, we saw a new variant – which came from outside and developed here – and led to the huge surge in the number of cases. We know the virus will continue to mutate. Aggressive surveillance in hotspots is required,” the AIIMS chief said.
“Mini-lockdown in any part of the country, which witnessed a surge and a rise in positivity rate beyond 5 percent, will be required. Unless we’re vaccinated, we’re vulnerable in the coming months,” he underlined, stressing that “testing, tracking, and treating” should be the focus in hotspots.
“We have to factor in human behavior while unlocking, which needs to be done in a graded manner,” Dr Guleria stressed.
On the spread of the Delta variant in the United Kingdom, which is now facing a third wave, he said, “Virus is still mutating, we need to be careful”.
The highly transmissible variant first identified in India is now making up 99 percent of fresh COVID-19 cases in the UK, news agency PTI reported.
The gap between the new waves is shortening and it’s “worrying”, Dr Guleria said.
“During the first wave (in India), the virus was not spreading that rapidly… all that changed during the second wave, and the virus became much more infectious. Now the Delta variant that’s spreading is much more infectious. Faster spread is likely,” said the AIIMS chief.
A debilitating second wave had led to the shortage of hospital beds and medical supplies in various parts of India. SOS messages on social media had caught the world’s attention with many nations coming forward to help. Several states have now eased the restrictions after weeks of strict curbs; however, preparations are on against the third wave.
In Maharashtra, experts have now warned that at its peak, the third wave of the virus could cause 8 lakh active cases in the state, which currently has around 1.4 lakh patients.
“When there is a huge increase in the number of cases, shortage of (hospital) beds follows. The strategy should be multi-pronged – we have to make sure fresh cases don’t rise. Any healthcare system globally will tend to collapse with the unprecedented rise in infections,” Dr. Guleria said.
Does India need to rethink its 12-16 week gap decision between two doses of Covishied, a vaccine the country is largely dependent on? “Nothing is written in stone. We will have to look at new strategies. But we need to have strong data to take that decision,” the AIIMS chief said.
The decision should be driven by science and not the shortage of doses, he suggested.
The United Kingdom adopted the one-shot strategy not only for AstraZeneca (which is being used as Covishield in India), but also for Pfizer, Dr. Guleria pointed out.
“One-shot strategy may not be a bad strategy as it can give protection to larger number of people,” Dr. Guleria said.
